Klinik für Anaesthesiologie, Klinikum der Universität München, Campus Großhadern
Welcome,         Profile    Billing    Logout  
 1 Trial 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Krenn, Katharina
NCT03567577 / 2017-003855-47: Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS

Recruiting
2
95
Europe
Solnatide 25 mg powder for reconstitution for solution for inhalation, AP301, 0.9% Saline Solution
Apeptico Forschung und Entwicklung GmbH
ARDS
12/24
12/24
PEPPER, NCT03334006 / 2016-001788-34: Prospective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis

Recruiting
2
200
Europe
Pentaglobin®/Standard of Care
RWTH Aachen University, Biotest
Peritonitis, Sepsis, Septic Shock
09/27
03/28
NCT05222542: Angiotensin Metabolite Profile After Subarachnoid Hemorrhage

Recruiting
N/A
60
Europe
Sampling of plasma and cerebrospinal fluid at specified time points
Dr. Roman Ullrich, Austrian Science Fund (FWF)
Subarachnoid Hemorrhage, Aneurysmal
02/25
02/25
Fischer, Bernhard
NCT03567577 / 2017-003855-47: Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS

Recruiting
2
95
Europe
Solnatide 25 mg powder for reconstitution for solution for inhalation, AP301, 0.9% Saline Solution
Apeptico Forschung und Entwicklung GmbH
ARDS
12/24
12/24
Frank, Sandra
ARISS, NCT03869385: Albumin Replacement Therapy in Septic Shock

Terminated
3
440
Europe
Albutein® 200 g/L or Plasbumin® 20, Human Albumin 20%
Jena University Hospital, German Research Foundation, Instituto Grifols, S.A., University Hospital Goettingen, SepNet - Critical Care Trials Group, Center for Sepsis Control and Care, Germany
Septic Shock
07/22
06/23
AGNES-19, NCT05156671: Adrecizumab (HAM8101) to Improve Prognosis and Outcomes in COVID-19 Trial

Terminated
2
16
Europe
Adrecizumab (HAM 8101), Placebo, Saline
Universitätsklinikum Hamburg-Eppendorf
COVID-19
08/23
11/23
NCT03567577 / 2017-003855-47: Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS

Recruiting
2
95
Europe
Solnatide 25 mg powder for reconstitution for solution for inhalation, AP301, 0.9% Saline Solution
Apeptico Forschung und Entwicklung GmbH
ARDS
12/24
12/24

Download Options